Skip to main content
Premium Trial:

Request an Annual Quote

Illumina and Canadian Children's Hospital Partner for Newborn Screening

NEW YORK (GenomeWeb News) - Illumina said today that it will work with the Children's Hospital of Eastern Ontario to develop molecular tests that would screen infants for spinal muscular atrophy and blood diseases.
 
Under the terms of the agreement, Illumina will hold the commercial rights for any assays it develops with the CHEO, which is located in Ottawa.
 
The research collaboration calls for Illumina to use its VeraCode technology on its BeadXpress reader initially to screen for hemaglobinopathies, which are genetic conditions causing blood disorders such as sickle-cell anemia and thalassemia. 
 
Illumina said that spinal muscular atrophy is the number-one genetic killer of infants and toddlers, but added that there is hope that it may be treatable if the mutation causing it is detected early enough.
 
The company said CHEO screens roughly 135,000 newborns for 27 different diseases every year.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.